Search Tag: heart failure

Executive Health Management

Heart Failure – Noninvasive Hemodynamic Monitoring on the Rise

2020 09 Mar

Heart Failure (HF) is a major and public health problem as it affects at least 26 million people worldwide and will dramatically increase with an ageing population. Currently 5.7 million people suffer from HF in the US with an expected 46% increase in prevalence by 2030.[1] This is an alarming number especially when accounting for increasing health... Read more

Cardiology Management

Innovation in Heart Failure: from Pills to Devices

2020 27 Feb

Heart failure is a common disorder affecting millions of people globally. Over the past three decades, the prevalence of heart failurehas been increasing primarily because of the advancing age of the population and advances in medicine, which is allowing patients with hypertension, myocardial infarction, end-stage renal disease, and diabetes to live... Read more

Executive Health Management

Bright Ideas

2020 29 Jan

HealthManagement.org rounds up exciting developments that have all the characteristics of game-changers for healthcare. What do you think? AI Breast Cancer Diagnosis Matches Two Doctors A study suggested that AI diagnoses breast cancer from mammograms more accurately than radiologists.A computer, specially designed and trained by... Read more

Cardiology Management

Beta Blockers and Heart Failure Hospitalisations

2019 07 Dec

Nearly six million Americans have heart failure, a leading driver of health care costs in the United States. The "stiff heart" heart failure variant accounts for about half of all cases and the vast majority of such patients take beta-blocker medications despite unclear benefit from their regular use. A new publication in JAMA Network Open links use... Read more

Cardiology Management

Machine Learning Helps Predict Risk of Heart Failure

2019 20 Sep

Heart failure is a common complication in patients suffering from Type 2 Diabetes (T2D). Recently, new medicines have been developed to offset these risks; however, finding effective strategies to identify which T2D patients are most at risk has been difficult.    Researchers at Brigham and Women’s Hospital and UT Southwestern Medical Centre have... Read more

Cardiology Management

#ESCCongress: PARAGON-HF Trial Misses Endpoint

2019 01 Sep

Findings from the PARAGON-HF trial were presented in the first hot-line session at the ESC Congress today in Paris. Investigators from Brigham and Women's Hospital presented the results of the Prospective Comparison of ARNI with ARB Global Outcome in HF With Preserved Ejection Fraction (PARAGON-HF). This is the largest, randomised clinical trial... Read more

Cardiology Management

#ESCCongress Preview: DAPA-HF Trial

2019 29 Aug

The DAPA-HF trial is the first heart failure outcomes trial with dapagliflozin, an SGLT2 inhibitor, in patients with and without Type-2 diabetes. Findings from the trial will be presented at the ESC Congress next week.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure... Read more

Executive Health Management

The Future of Cardiovascular Disease Treatment and Management

2019 26 Aug

Arthur M. Feldman, MD, PhD, Laura H. Carnell Professor of Medicine at the Lewis Katz School of Medicine at Temple University, has been recognised with the 2019 Distinguished Scientist Award-Basic Domain by the American College of Cardiology. Prof. Feldman has received this honour due to his contribution towards improving cardiovascular health and... Read more

Cardiology Management

Inotropic Agents for Heart Failure - Wishful Thinking?

2019 26 Aug

Summary: Calcium activation and calcium sensitivity in the failing myocardium.   Historically, treatment of heart failure with inotropic agents started with the employment of extracts of foxglove, which contained a mixture of cardiac glycosides. With their low therapeutic margin due to a resulting ionic dysbalance though, cardiac glycosides... Read more

Cardiology Management

#ESCCongress Preview: PARAGON-HF Trial

2019 10 Aug

Topline findings from the Phase III PARAGON-HF study have just been announced. Full results of the trial will be presented at the ESC Congress 2019 in September.  The  PARAGON-HF trial  in heart failure patients with preserved ejection fraction (HFPEF) investigates the safety and efficacy of sacubitril/valsartan versus the active comparator... Read more